Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients

Abstract

Matrix metalloprotease-9 (MMP-9; 92 kDa type IV collaganase, gelatinase B) is regarded as, important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodelling events. In this study we evaluate the prognostic value of MMP-9, by immunoperoxidase staining in a series of 210 breast cancer tissues. The results were quantitated using the HSCORE system, which consider both staining intensity and the percentage of cells stained at given intensities. MMP-9 status was compared with the concentration of cytosolic Cathepsin-D and with other established prognostic factors, in terms of disease free survival and overall survival. The median follow-up period was 62 months. MMP-9 staining was observed primarily in cancer cells, and to a lesser degree in surrounding stromal cells. MMP-9 expression was not detected in normal breast tissue. Levels of MMP-9 expression below the cut-off point were more frequently observed in larger (P = 0.014), invasive ductal histologic (P = 0.037), progesterone receptor (PR)-negative and PR-strong positive tumours (P< 0.001), as well as samples belonging to patients with stage III-IV disease (P = 0.009) and age 45-55 years (P = 0.011). In univariate analysis, node-negative breast cancer patients with tumors positive for MMP-9 had a considerable reduction in risk for relapse (RR = 0.45;P = 0.039) or death (RR = 0.32;P = 0.009). Multivariate analysis indicated that MMP-9 status was an independent favourable predictor of OS (RR = 0.47;P = 0.034) in node-negative but not in node-positive patients. Our results suggest that MMP-9 may be an independent favourable prognostic factor in node-negative breast cancer patients. The overexpression of MMP-9 in breast cancer may be also used as a marker to subdivide node negative breast cancer patients in order to determine the optimal treatment modality.

References 49

1. 1.

   Ardavanis A., Scorilas A., Amanatidou A., Gerakini F., Missitzis I., Garoufali A., Pissakas G., Pateras C., Apostolikas N., Rigatos G. Cathepsin D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Res. 1997;17(2B):1405-1409.

   Not in our library

2. 2.

   Bajou K., Noël A., Gerard R. D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N. E., Carmeliet P., Collen D. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4(8):923-928.

   Not in our library10.1038/nm0898-923

3. 3.

   Benaud C., Dickson R. B., Thompson E. W. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat. 1998;50(2):97-116.

   Not in our library10.1023/a:1006061115909

4. 4.

   Bianchi E., Cohen R. L., Dai A., Thor A. T., Shuman M. A., Smith H. S. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995;60(5):597-603.

   Not in our library10.1002/ijc.2910600505

5. 5.

   Blavier L., DeClerck Y. A. Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development. Mol Biol Cell. 1997;8(8):1513-1527.

   Not in our library10.1091/mbc.8.8.1513

6. 6.

   Daidone M. G., Silvestrini R., D'Errico A., Di Fronzo G., Benini E., Mancini A. M., Garbisa S., Liotta L. A., Grigioni W. F. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer. 1991;48(4):529-532.

   Not in our library10.1002/ijc.2910480409

7. 7.

   Duffy M. J., Blaser J., Duggan C., McDermott E., O'Higgins N., Fennelly J. J., Tschesche H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer. 1995;71(5):1025-1028.

   Not in our library10.1038/bjc.1995.197

8. 8.

   Elashry-Stowers D., Zava D. T., Speers W. C., Edwards D. P. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies. Cancer Res. 1988;48(22):6462-6474.

   Not in our library

9. 9.

   Fridman R., Toth M., Peña D., Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55(12):2548-2555.

   Not in our library

10. 10.

    Garbett E. A., Reed M. W., Brown N. J. Proteolysis in human breast and colorectal cancer. Br J Cancer. 1999;81(2):287-293.

    Not in our library10.1038/sj.bjc.6690689

11. 11.

    Hanemaaijer R., Sier C. F., Visser H., Scholte L., van Lent N., Toet K., Hoekman K., Verheijen J. H. MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann N Y Acad Sci. 1999;878:141-149.

    Not in our library10.1111/j.1749-6632.1999.tb07680.x

12. 12.

    Heppner K. J., Matrisian L. M., Jensen R. A., Rodgers W. H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149(1):273-282.

    Not in our library

13. 13.

    Hewitt R., Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 1996;49(1-3):163-173.

    Not in our library10.1159/000468623

14. 14.

    Jonat C., Rahmsdorf H. J., Park K. K., Cato A. C., Gebel S., Ponta H., Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62(6):1189-1204.

    Not in our library10.1016/0092-8674(90)90395-u

15. 15.

    Jones J. L., Glynn P., Walker R. A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189(2):161-168.

    Not in our library10.1002/(sici)1096-9896(199910)189:2<161::aid-path406>3.0.co;2-2

16. 16.

    Karameris A., Panagou P., Tsilalis T., Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med. 1997;156(6):1930-1936.

    Not in our library10.1164/ajrccm.156.6.9612046

17. 17.

    Kute T. E., Huske M. S., Shore A., Rhyne A. L. Improvements in steroid receptor assays including rapid computer analysis of data. Anal Biochem. 1980;103(2):272-279.

    Not in our library10.1016/0003-2697(80)90609-0

18. 18.

    Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F., Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64(9):1914-1921.

    Not in our library10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g

19. 19.

    Magklara A., Scorilas A., Stephan C., Kristiansen G. O., Hauptmann S., Jung K., Diamandis E. P. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000;56(3):527-532.

    Not in our library10.1016/s0090-4295(00)00621-x

20. 20.

    Mira E., Mañes S., Lacalle R. A., Márquez G., Martínez-A C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology. 1999;140(4):1657-1664.

    Not in our library10.1210/endo.140.4.6623

21. 21.

    Nelson A. R., Fingleton B., Rothenberg M. L., Matrisian L. M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135-1149.

    Not in our library10.1200/jco.2000.18.5.1135

22. 22.

    Nielsen B. S., Sehested M., Kjeldsen L., Borregaard N., Rygaard J., Danø K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest. 1997;77(4):345-355.

    Not in our library

23. 23.

    Nielsen B. S., Sehested M., Timshel S., Pyke C., Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest. 1996;74(1):168-177.

    Not in our library

24. 24.

    Nielsen B. S., Timshel S., Kjeldsen L., Sehested M., Pyke C., Borregaard N., Danø K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer. 1996;65(1):57-62.

    Not in our library10.1002/(sici)1097-0215(19960103)65:1<57::aid-ijc10>3.0.co;2-f

25. 25.

    Pacheco M. M., Mourão M., Mantovani E. B., Nishimoto I. N., Brentani M. M. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis. 1998;16(7):577-585.

    Not in our library10.1023/a:1006580415796

26. 26.

    Ree A. H., Bjørnland K., Brünner N., Johansen H. T., Pedersen K. B., Aasen A. O., Fodstad O. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis. 1998;16(3):205-215.

    Not in our library10.1023/a:1006584624061

27. 27.

    Remacle A. G., Noël A., Duggan C., McDermott E., O'Higgins N., Foidart J. M., Duffy M. J. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998;77(6):926-931.

    Not in our library10.1038/bjc.1998.153

28. 28.

    Rha S. Y., Kim J. H., Roh J. K., Lee K. S., Min J. S., Kim B. S., Chung H. C. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat. 1997;43(2):175-181.

    Not in our library10.1023/a:1005701231871

29. 29.

    Rha S. Y., Yang W. I., Kim J. H., Roh J. K., Min J. S., Lee K. S., Kim B. S., Chung H. C. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 1998;5(4):875-879.

    Not in our library10.3892/or.5.4.875

30. 30.

    Salamonsen L. A., Butt A. R., Hammond F. R., Garcia S., Zhang J. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab. 1997;82(5):1409-1415.

    Not in our library10.1210/jcem.82.5.3920

31. 31.

    Scorilas A., Black M. H., Talieri M., Diamandis E. P. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun. 2000;278(2):349-359.

    Not in our library10.1006/bbrc.2000.3807

32. 32.

    Scorilas A., Diamandis E. P., Levesque M. A., Papanastasiou-Diamandi A., Khosravi M. J., Giai M., Ponzone R., Roagna R., Sismondi P., López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clin Cancer Res. 1999;5(7):1778-1785.

    Not in our library

33. 33.

    Scorilas A., Talieri M., Ardavanis A., Courtis N., Dimitriadis E., Yotis J., Tsiapalis C. M., Trangas T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res. 2000;60(19):5427-5433.

    Not in our library

34. 34.

    Scorilas A., Trangas T., Yotis J., Pateras C., Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer. 1999;81(8):1385-1391.

    Not in our library10.1038/sj.bjc.6693404

35. 35.

    Scorilas A., Yotis J., Gouriotis D., Keramopoulos A., Ampela K., Trangas T., Talieri M. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res. 1993;13(5C):1895-1900.

    Not in our library

36. 36.

    Scorilas A., Yotis J., Pateras C., Trangas T., Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res. 1999;5(4):815-821.

    Not in our library

37. 37.

    Scorilas A., Yotis J., Stravolemos K., Gouriotis D., Keramopoulos A., Ampela K., Talieri M., Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res. 1995;15(4):1543-1547.

    Not in our library

38. 38.

    Sugiura Y., Shimada H., Seeger R. C., Laug W. E., DeClerck Y. A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998;58(10):2209-2216.

    Not in our library

39. 39.

    Takeha S., Fujiyama Y., Bamba T., Sorsa T., Nagura H., Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res. 1997;88(1):72-81.

    Not in our library10.1111/j.1349-7006.1997.tb00304.x

40. 40.

    Thorpe S. M., Christensen I. J., Rasmussen B. B., Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer. 1993;29A(7):971-977.

    Not in our library10.1016/s0959-8049(05)80204-7

Cited by papers we hold 5

• Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis · 2021
  No notice
• The regulation of MMP targeting to invadopodia during cancer metastasis · 2015
  No notice
• Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis · 2015
  No notice
• Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer · 2014
  No notice
• Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.